AngioDynamics (ANGO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Oct, 2026Executive summary
Virtual annual meeting scheduled for Nov. 17, 2026, at 12:00 p.m. EDT; voting deadline is Nov. 16, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Shareholders will vote on two Class II director nominees, auditor ratification, an advisory say-on-pay proposal, and an amendment increasing shares available under the 2020 Equity Incentive Plan.
Board of directors and corporate governance
Eileen O. Auen and Jan Stern Reed are nominated as Class II directors for three-year terms; the board recommends voting for both.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AngioDynamics
- Four shareholder votes coincide with a CEO transition and proposed 1M-share plan increase.ANGO
Proxy filing - Med Tech-led growth lifted Q1 sales and EBITDA as FY27 guidance held.ANGOQ1 2027
- MedTech growth, platform expansion, and margin gains drive a strong FY27 outlook.ANGOCanaccord Genuity's 46th Annual Growth Conference
- Med Tech drove 18.4% growth and margin gains, with 2027 guidance targeting further expansion.ANGOQ4 2026
- 12.2% revenue growth, 26.1% Med Tech gain, improved margin, and raised FY26 guidance.ANGOQ1 2026
- Auryon, AngioVac, and AlphaVac platforms drive rapid growth and strong profitability outlook.ANGOInvestor Update
- Transformation to a med tech growth leader is driving profitability and global expansion.ANGO43rd Annual J.P. Morgan Healthcare Conference 2025
- Q3 FY2025 saw 9.2% sales growth, margin expansion, and raised guidance.ANGOQ3 2025
- Q2 FY25 sales up 9.2% YoY, Med Tech up 25%, and profitability outlook raised.ANGOQ2 2025